Velan Capital Investment Management LP Sells 1,951,514 Shares of InspireMD, Inc. $NSPR

Velan Capital Investment Management LP reduced its holdings in shares of InspireMD, Inc. (NYSE:NSPR) by 92.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,138 shares of the company’s stock after selling 1,951,514 shares during the quarter. Velan Capital Investment Management LP owned 0.32% of InspireMD worth $104,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new stake in shares of InspireMD in the 1st quarter worth about $29,000. XTX Topco Ltd acquired a new position in InspireMD during the 4th quarter valued at about $30,000. Virtu Financial LLC bought a new stake in InspireMD during the 4th quarter worth approximately $31,000. Creative Planning bought a new stake in InspireMD during the 2nd quarter worth approximately $44,000. Finally, Legato Capital Management LLC purchased a new stake in shares of InspireMD in the fourth quarter worth approximately $48,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Stock Down 7.5%

Shares of InspireMD stock opened at $0.84 on Thursday. InspireMD, Inc. has a 52 week low of $0.63 and a 52 week high of $2.56. The business has a 50 day moving average price of $0.77 and a 200-day moving average price of $1.12. The company has a market cap of $39.06 million, a PE ratio of -1.12 and a beta of 0.82.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.